Weil Company Inc. Raises Stake in Pfizer Inc. (NYSE:PFE)

Weil Company Inc. boosted its stake in Pfizer Inc. (NYSE:PFE) by 4.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,484 shares of the biopharmaceutical company’s stock after acquiring an additional 300 shares during the quarter. Weil Company Inc.’s holdings in Pfizer were worth $235,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Norges Bank purchased a new position in Pfizer in the 4th quarter worth approximately $2,219,532,000. BlackRock Inc. boosted its stake in shares of Pfizer by 2.2% during the 1st quarter. BlackRock Inc. now owns 405,733,970 shares of the biopharmaceutical company’s stock valued at $14,699,742,000 after buying an additional 8,760,458 shares during the last quarter. Morgan Stanley boosted its stake in shares of Pfizer by 16.4% during the 4th quarter. Morgan Stanley now owns 53,610,111 shares of the biopharmaceutical company’s stock valued at $1,973,389,000 after buying an additional 7,540,245 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Pfizer by 12.1% during the 4th quarter. Bank of New York Mellon Corp now owns 64,756,839 shares of the biopharmaceutical company’s stock valued at $2,383,700,000 after buying an additional 6,965,496 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $162,707,000. Hedge funds and other institutional investors own 64.22% of the company’s stock.

In other news, SVP Jennifer B. Damico sold 2,500 shares of the stock in a transaction on Wednesday, May 5th. The stock was sold at an average price of $40.82, for a total value of $102,050.00. Following the completion of the transaction, the senior vice president now owns 13,748 shares of the company’s stock, valued at $561,193.36. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.05% of the company’s stock.

Several equities analysts have recently commented on PFE shares. The Goldman Sachs Group set a $45.00 target price on Pfizer and gave the company a “neutral” rating in a research note on Monday, May 24th. Berenberg Bank reiterated a “neutral” rating and set a $38.00 target price on shares of Pfizer in a research note on Tuesday, March 23rd. SVB Leerink upped their price target on Pfizer from $39.00 to $43.00 and gave the company a “market perform” rating in a research report on Wednesday, May 5th. Barclays upped their price target on Pfizer from $37.00 to $40.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 5th. Finally, Royal Bank of Canada started coverage on Pfizer in a research report on Wednesday, April 7th. They set a “sector perform” rating and a $42.00 price target on the stock. Twelve analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $39.73.

Shares of NYSE PFE opened at $40.56 on Friday. Pfizer Inc. has a 1-year low of $31.61 and a 1-year high of $43.08. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.16. The stock has a fifty day moving average of $38.76. The firm has a market capitalization of $227.04 billion, a price-to-earnings ratio of 20.76, a PEG ratio of 1.42 and a beta of 0.74.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 4th. The biopharmaceutical company reported $0.93 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.15. Pfizer had a return on equity of 24.55% and a net margin of 22.09%. The firm had revenue of $14.58 billion for the quarter, compared to analyst estimates of $13.41 billion. During the same period last year, the company earned $0.80 earnings per share. The firm’s revenue for the quarter was up 44.6% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post 3.69 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, June 4th. Stockholders of record on Friday, May 7th were paid a $0.39 dividend. The ex-dividend date of this dividend was Thursday, May 6th. This represents a $1.56 annualized dividend and a dividend yield of 3.85%. Pfizer’s payout ratio is 70.27%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Recommended Story: What is a Candlestick Chart?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.